.png)
100 IR & 300 IR or 300 IR, sublingual tablets
5-grass pollen allergen extract
5-grass pollen allergen extract
At Stallergenes Greer,
we partner with Health
Care Professionals
to support patients
through their
treatment cycle
we partner with Health
Care Professionals
to support patients
through their
treatment cycle
Go Inside Oralair
*5-grass pollen allergen extract is a mix of cocksfoot (Dactylis glomerata L.), sweet vernal grass
(Anthoxanthum odoratum L.), rye grass (Lolium perenne L.), meadow grass (Poa pratensis L.)
and timothy (Phleum pratense L.).
(Anthoxanthum odoratum L.), rye grass (Lolium perenne L.), meadow grass (Poa pratensis L.)
and timothy (Phleum pratense L.).
2024_012EN01_March 2024
.svg)
Oralair® 5-grass pollen allergen
extract with an adapted pre-coseasonal
protocol mimics the diverse
real-life exposure of patients
allergic to grass pollen1-3
extract with an adapted pre-coseasonal
protocol mimics the diverse
real-life exposure of patients
allergic to grass pollen1-3
Oralair® is a sublingual
immunotherapy tablet with
a flexible initiation protocol
to improve tolerability1,4-7
immunotherapy tablet with
a flexible initiation protocol
to improve tolerability1,4-7
Highly potent,4* Oralair® demonstrated
results as early as 1 month7** and
meaningful improvements over
time for patients8,9
results as early as 1 month7** and
meaningful improvements over
time for patients8,9
Oralair® has shown carry-over effects
for up to 6 years after treatment
cessation10,11*
for up to 6 years after treatment
cessation10,11*
Let's get personal
*In vitro study. Highly potent based on allergen potency evaluated quantitatively without any validated clinical consequences.
**Results of the secondary endpoints observed in the controlled conditions of an Allergen Challenge Chamber (ACC). The single allergen source, the lack of seasonal priming,
subject demographics closed by the ACC area, trial context and short duration might not reflect the natural pathological process and environmental factors contributing to an
individual’s development of allergic rhinoconjunctivitis.
**Results of the secondary endpoints observed in the controlled conditions of an Allergen Challenge Chamber (ACC). The single allergen source, the lack of seasonal priming,
subject demographics closed by the ACC area, trial context and short duration might not reflect the natural pathological process and environmental factors contributing to an
individual’s development of allergic rhinoconjunctivitis.
* In this study Oralair® was investigated as one product in a treatment group compared to a non-AIT control group and is based on a retrospective
German database analysis of health and prescription data.
German database analysis of health and prescription data.
“My name’s Marie. I love my job, but every time spring comes around, my
allergy symptoms hold me back from getting on and achieving all I want to."
Treat her
The following medical history is fictional. The presentation is based on typically occurring
circumstances. The treatment and the success of the therapy depicted represent an idealized
course. This possible course of therapy has been confirmed by clinical studies. Nevertheless, each
patient and each course of disease is highly individual and a corresponding effect cannot be
expected and guaranteed for all patients.
circumstances. The treatment and the success of the therapy depicted represent an idealized
course. This possible course of therapy has been confirmed by clinical studies. Nevertheless, each
patient and each course of disease is highly individual and a corresponding effect cannot be
expected and guaranteed for all patients.
33 years young lady living
in Spain
International journalist
(Italian specialist)
Single, no child, no pets
Passion for Middle East
where she spends holidays
Before
“My name’s Marie. I love my job, but every time
spring comes around, my allergy
symptoms hold me back from
getting on and achieving all I
want to. Each year I’ve needed more
antihistamines to get through the
season.
Now that I’ve started AIT, could I
finally get control of my
symptoms and enjoy spring?
spring comes around, my allergy
symptoms hold me back from
getting on and achieving all I
want to. Each year I’ve needed more
antihistamines to get through the
season.
Now that I’ve started AIT, could I
finally get control of my
symptoms and enjoy spring?
Help her to love a life beyond allergy
Clinical History
For 5 years, rhinitis symptoms (frequent sneezing salvos, rhinorrhea, itchy nose and throat , itchy and red eyes, fatigue) occurring during Spring and early Summer time, with fatigue and irritability at work. She was treated with:
- Oral H1-antihistamines
- Cromoglycate eye drops
- Nasal corticosteroids
(which she presumably does not take)
Clinical Exam
No congested nasal
mucosa and watery
secretions
No red conjunctiva
No wheeze
Diagnosis
Diagnosis:
Allergic rhinitis to grass pollen
Polysensitization to cat danders
Cross-reactivity with Cypress,
Parietaria (profilin)
Polysensitization to cat danders
Cross-reactivity with Cypress,
Parietaria (profilin)
Treat
Physician
Recommendation
Recommendation
Allergen
avoidance
avoidance
Symptomatic
treatment
treatment
Sublingual
immunotherapy
liquid formulation
immunotherapy
liquid formulation
Sublingual
immunotherapy
tablet formulation
immunotherapy
tablet formulation
Patient's Choice
Symptomatic treatment
Sublingual immunotherapy
tablet formulation
Oralair® is the only grass pollen AIT
tablet with an established
discontinuous treatment protocol
tablet with an established
discontinuous treatment protocol
Initiate Treatment
Early results
“For the first time in years, spring feels
hopeful. I have been taking my AIT for 4
months leading up to the beginning of the
season. Now that it's here, even as the pollen
count rises, my symptoms reduce. This could
be my year. I'm going to put my best foot
forward - because I can now, without my
allergy holding me back.”
hopeful. I have been taking my AIT for 4
months leading up to the beginning of the
season. Now that it's here, even as the pollen
count rises, my symptoms reduce. This could
be my year. I'm going to put my best foot
forward - because I can now, without my
allergy holding me back.”
Maintenance
Maintained
Results
Results
“It’s been two years since I finished AIT and I’m loving my reduced
symptoms life. Ever since I said goodbye to those awful, stifling symptoms, I’ve been
thriving at work in every season, without setbacks. And guess what? Today we’re
celebrating my promotion. Springtime is my time now.”
Life beyond allergy
Every patientdeserves to live a life beyond allergy
Potential AIT benefits over time
Theoretical concept adapted with permission from Spriggs K. et al.12
Oralair® is a sublingual immunotherapy
tablet with a flexible initiation protocol
to improve tolerability1,4-7
tablet with a flexible initiation protocol
to improve tolerability1,4-7
Highly potent4*, Oralair® demonstrated
results as early as 1 month7** and meaningful
improvements over time for patients8,9
results as early as 1 month7** and meaningful
improvements over time for patients8,9
Oralair® has shown
carry-over effects
for up to 6 years after
treatment cessation10,11***
carry-over effects
for up to 6 years after
treatment cessation10,11***
Learn more about safety
*In vitro study. Highly potent based on allergen potency evaluated quantitatively without any validated clinical consequences.
**Results of the secondary endpoints observed in the controlled conditions of an Allergen Challenge Chamber (ACC). The single allergen
source, the lack of seasonal priming, subject demographics closed by the ACC area, trial context and short duration might not reflect the
natural pathological process and environmental factors contributing to an individual’s development of allergic rhinoconjunctivitis.
***In this study Oralair® was investigated as one product in a treatment group compared to a non-AIT control group and is based on
a retrospective German database analysis of health and prescription data.
**Results of the secondary endpoints observed in the controlled conditions of an Allergen Challenge Chamber (ACC). The single allergen
source, the lack of seasonal priming, subject demographics closed by the ACC area, trial context and short duration might not reflect the
natural pathological process and environmental factors contributing to an individual’s development of allergic rhinoconjunctivitis.
***In this study Oralair® was investigated as one product in a treatment group compared to a non-AIT control group and is based on
a retrospective German database analysis of health and prescription data.
Every patientdeserves to live a life beyond allergy
Summary of the safety profile1
During treatment with ORALAIR, patients are exposed to allergens
that may cause application-site reactions and/or systemic allergic
symptoms. Application-site reactions (e.g. oral pruritus and throat
irritation) may therefore be expected during the period of therapy.
If a patient experiences an application-site reaction, symptomatic
treatment (e.g. with antihistamines) may be considered. Please consult section 4.8 of the SmPC for full safety details.
Let us tell you all about it
ORALAIR 100 IR & 300 IR, sublingual tablets or ORALAIR 300 IR, sublingual tablets is:
• indicated in treatment of grass pollen allergic rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms, confirmed by a positive cutaneous test and/or a positive titre of the specific IgE to one of the grass pollen from the Pooideae grass homologous group1 … Read more Read less
• indicated in treatment of grass pollen allergic rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms, confirmed by a positive cutaneous test and/or a positive titre of the specific IgE to one of the grass pollen from the Pooideae grass homologous group1 … Read more Read less
